The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years

References

1. Ackermann G., Tang Y. J., Kueper R., Heisig P., Rodloff A. C., Silva J. Jr, Cohen S. H. 2001; Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 45:2348–2353 [View Article][PubMed]
   [Google Scholar]
2. Ackermann G., Degner A., Cohen S. H., Silva J. Jr, Rodloff A. C. 2003; Prevalence and association of macrolide-lincosamide-streptogramin B (MLS_B) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 51:599–603 [View Article][PubMed]
   [Google Scholar]
3. Barbut F., Decré D., Lalande V., Burghoffer B., Noussair L., Gigandon A., Espinasse F., Raskine L., Robert J.& other authors ( 2005; Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 54:181–185 [View Article][PubMed]
   [Google Scholar]
4. Barbut F., Mastrantonio P., Delmée M., Brazier J., Kuijper E., Poxton I.European Study Group on Clostridium difficile (ESGCD) 2007; Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13:1048–1057 [View Article][PubMed]
   [Google Scholar]
5. Bauer M. P., Notermans D. W., van Benthem B. H., Brazier J. S., Wilcox M. H., Rupnik M., Monnet D. L., van Dissel J. T., Kuijper E. J.ECDIS Study Group 2011; Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:63–73 [View Article][PubMed]
   [Google Scholar]
6. Bourgault A. M., Lamothe F., Loo V. G., Poirier L.CDAD-CSI Study Group 2006; In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob Agents Chemother 50:3473–3475 [View Article][PubMed]
   [Google Scholar]
7. Cheknis A. K., Zukowski W. E., Petrella A. K., Nagaro J., Sambol S. P., Figueroa I., Li L.Q., Perdue E., Gelone S. P. other authors 2009; Prevalence of REA types of Clostridium difficile from U.S. hospitals (2006–2009). In Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy abstract K-2075 San Francisco, CA:
   [Google Scholar]
8. CLSI 2012; Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard M11–A8. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
9. CLSI 2013; Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement M100–S23. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
10. Dridi L., Tankovic J., Burghoffer B., Barbut F., Petit J. C. 2002; gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46:3418–3421 [View Article][PubMed]
    [Google Scholar]
11. Drudy D., Quinn T., O’Mahony R., Kyne L., O’Gaora P., Fanning S. 2006; High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58:1264–1267 [View Article][PubMed]
    [Google Scholar]
12. Heddle J., Maxwell A. 2002; Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob Agents Chemother 46:1805–1815 [View Article][PubMed]
    [Google Scholar]
13. Huang H., Fang H., Weintraub A., Nord C. E. 2009a; Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 15:1170–1173 [View Article][PubMed]
    [Google Scholar]
14. Huang H., Weintraub A., Fang H., Nord C. E. 2009b; Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 34:516–522 [View Article][PubMed]
    [Google Scholar]
15. Huang H., Wu S., Wang M., Zhang Y., Fang H., Palmgren A. C., Weintraub A., Nord C. E. 2009c; Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents 33:339–342 [View Article][PubMed]
    [Google Scholar]
16. Kato H., Kato N., Watanabe K., Iwai N., Nakamura H., Yamamoto T., Suzuki K., Kim S. M., Chong Y., Wasito E. B. 1998; Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 36:2178–2182[PubMed]
    [Google Scholar]
17. Kim H., Jeong S. H., Roh K. H., Hong S. G., Kim J. W., Shin M. G., Kim M. N., Shin H. B., Uh Y.& other authors ( 2010; Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 30:491–497 [View Article][PubMed]
    [Google Scholar]
18. Lyerly D. M., Krivan H. C., Wilkins T. D. 1988; Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1:1–18[PubMed]
    [Google Scholar]
19. McDonald L. C., Killgore G. E., Thompson A., Owens R. C. Jr, Kazakova S. V., Sambol S. P., Johnson S., Gerding D. N. 2005; An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433–2441 [View Article][PubMed]
    [Google Scholar]
20. O’Donoghue C., Kyne L. 2011; Update on Clostridium difficile infection. Curr Opin Gastroenterol 27:38–47 [View Article][PubMed]
    [Google Scholar]
21. Sawabe E., Kato H., Osawa K., Chida T., Tojo N., Arakawa Y., Okamura N. 2007; Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur J Clin Microbiol Infect Dis 26:695–703 [View Article][PubMed]
    [Google Scholar]
22. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J. S., Barbut F., Delmée M., Kuijper E., Poxton I. R.European Study Group on Clostridium difficile (ESGCD) 2008; Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57:784–789 [View Article][PubMed]
    [Google Scholar]
23. Spigaglia P., Barbanti F., Dionisi A. M., Mastrantonio P. 2010; Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol 48:2892–2896 [View Article][PubMed]
    [Google Scholar]
24. Stubbs S. L., Brazier J. S., O’Neill G. L., Duerden B. I. 1999; PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463[PubMed]
    [Google Scholar]
25. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M. 2000; Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 186:307–312 [View Article][PubMed]
    [Google Scholar]
26. Tae C. H., Jung S. A., Song H. J., Kim S. E., Choi H. J., Lee M., Hwang Y., Kim H., Lee K. 2009; The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci 24:520–524 [View Article][PubMed]
    [Google Scholar]